Transcript Highlights:

• pharmaceuticals is spent on marketing. pharmaceuticals is spent on marketing.
• <01:05:01.280> manufacturers<01:05:01.920> is pharmaceutical manufacturers is pharmaceutical
• and the pharmaceut pharmacy and the pharmaceutical<01:20:11.840> industry.
• Uh and that's pharmaceutical industry.
• <01:27:18.880> industry that it puts the pharmaceutical industry that it puts the pharmaceutical

Keywords: 1187, senate, all

Transcript Highlights:

• I don't know if we'll touch on this, but pharmaceutical-grade xylazine versus non-pharmaceutical-grade
• compounds that you would attain from a pharmacy or from a pharmaceutical distributor or a compounding
• The non-PG, as we call non-pharmaceutical-grade compounds.
• It's a difference between, you know, pharmaceutical-grade approved versus, you know, what's out there
• fentanyl and the non-pharmaceutical-grade fentanyl or the non-controlled production fentanyl.

Keywords: 995, all

Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.

Transcript Highlights:

• I'm Senior Director of State Affairs at Pharmaceutical Care Management Association, otherwise known as
• Pharmaceutical manufacturers are refusing to ship 340B-priced drugs to CHC, or community health center
• It also requires pharmaceutical manufacturers to ship 340B-priced drugs to pharmacy health centers and
• HDA is the national trade association representing pharmaceutical wholesale distributors.
• HDA is the national trade association representing pharmaceutical wholesale distributors.

Keywords: 995, all

Summary: The committee held a lengthy hearing on a large docket of pharmacy and drug-pricing bills, with most testimony focused on PBM reform, 340B drug discount program protections, specialty medication access, and medication adherence. Chair James Murphy and Senator Paul Feeney opened the hearing and took testimony from legislators, patient advocates, pharmacists, health center leaders, industry representatives, and policy groups. Several speakers described delays, denials, high out-of-pocket costs, and pharmacy closures tied to PBM practices, while others emphasized the importance of community health centers and independent pharmacies in serving patients. On the 340B program, supporters including Senator Eldridge, Senator Payano, Community Care Cooperative, Fenway Health, the Massachusetts League of Community Health Centers, and several community health center leaders argued that bills such as H. 1107 and S. 819 would stop discriminatory PBM and manufacturer practices, preserve contract pharmacy access, and protect safety-net providers that say they reinvest savings into care, pharmacy expansion, interpreter services, behavioral health, and other services. Opponents including PhRMA, the Community Liver Alliance, and a public policy analyst argued the program lacks transparency and accountability, has grown beyond its original purpose, and may benefit large hospitals and for-profit entities more than low-income patients. They urged more reporting and oversight rather than expanding protections. On PBM reform, testimony supported bills including H. 1157, H. 1234, S. 724, S. 831, and related measures that would require rebate pass-through, ban spread pricing, limit steering to PBM-owned pharmacies, and improve reimbursement for community pharmacies. Independent pharmacists and patients said current PBM practices raise costs, create administrative burdens, and threaten access to local pharmacies. PCMA, representing PBMs, opposed the reforms, arguing PBMs lower costs, that plan sponsors choose to contract with them, and that the Health Policy Commission and CHIA should complete their ongoing study before new mandates are adopted. The committee also heard support for H. 1322 and S. 734 on specialty medications, and for H. 781 and H. 1305 on medication synchronization to improve adherence. No votes or formal actions were taken during the hearing.

Transcript Highlights:

• ...asked the pharmaceutical companies to ask the U.S.
• for the top 10 CEOs of pharmaceutical for the top 10 CEOs of pharmaceutical manufacturer manufacturer
• All it's going to do is increase the bottom line of pharmaceutical manufacturers.
• This is funded through pharmaceutical companies providing these discounts to us.
• This is funded through pharmaceutical companies providing these discounts to us.

Keywords: 00:00:00 Call to Order/Roll Call 00:01:19 Discussion of 25RS HB 785 00:30:25 Roll Call Vote on 25RS HB 785 00:32:15 Discussion of 25RS HB 61 00:36:42 Roll Call Vote on 25RS HB 61 00:38:07 Discussion of 25RS HB 788 00:51:01 Discussion of 25RS SB 14 01:11:09 Discussion of 25RS HB 685 01:44:57 Adjournment, 958, all

Summary: The House Standing Committee on Health Services met with a quorum and took up House Bill 785, as amended by a committee substitute that combined language from HB 785 and HB 787. The bill was described as addressing Medicaid managed care organization (MCO) audits, provider contract notice and amendment procedures, mental health parity compliance, and related transparency requirements. Supporters said the measure would tighten notice to providers, limit repeated contract amendments and rate reductions, require more standardized audit procedures, and add reporting on Medicaid claims, appeals, and grievances. It also includes a provision requiring coverage of at least two evaluation-and-management billable services per physician per recipient per date of service, and a section addressing narcotic/opioid treatment program licensing and reimbursement language. Testimony in support came from Representative Kim Moore, John Inman of BrightView Health, Michelle Sandborne of the Children’s Alliance, and Kelly Cormic of RYSE. They argued that MCOs often use audits and recoupments in ways that are burdensome, opaque, and financially damaging to providers, especially smaller and rural ones. They cited examples of multiple audit requests in short timeframes, large record requests with short deadlines, delayed or absent feedback, and recoupments taken before appeals are resolved. They also said parity laws are not being consistently enforced and that the bill would give the Department of Insurance authority to suspend or revoke an MCO certificate of authority for willful or repeated parity violations. Committee members generally expressed support for provider protections and transparency, while asking for clarification on the narcotic treatment and E/M billing provisions. Tom Stevens of the Kentucky Association of Health Plans testified in opposition, saying the bill is complex to implement and should be handled through the broader Medicaid oversight work of House Bill 9, the MOAB. He said the issues raised were better suited for that bipartisan stakeholder process and noted the committee substitute had not yet been fully reviewed by his group. After discussion, the committee adopted the committee substitute and then moved to a vote on the bill; the roll call began, with several members recorded as voting yes, but the transcript cuts off before the final vote result is shown.

Transcript Highlights:

• Texas has over 13,000, nearly 14,000 jobs in the pharmaceutical industry. pharmaceutical development
• Those restrictions come from the pharmaceutical manufacturers themselves.
• The transparency, I mean, where is the transparency on the pharmaceuticals?
• Evidence supports the idea that pharmaceuticals are still making a lot of money.
• Their pharmaceutical coverage.

Bills: HB712, HB722, HB946, HB1687, HB1809, HB1899, HB2528, HB2583, HB2741, HB2750, HB3021, HB3150, HB3265, HB3658, HB3812, HB3960, HB4392, HB4432

Keywords: prostate cancer, health benefit plans, insurance coverage, cost sharing, preventive health care, auto insurance, total loss evaluation, disclosure, insurance materials, vehicle appraisal, HB 946, Texas Insurance Code, automobile insurance claims, oral release, written release, settlement agreement, claim release, property damage, bodily injury, psychological injury

Transcript Highlights:

• But also, more importantly, through the Commerce Department and meeting directly with pharmaceutical
• We have 4.2% of the world's population and we take 50% of the pharmaceutical drugs.
• We're the only country that allows full-scale pharmaceutical ads on TV.
• Let's not just do something for the pharmaceutical company. So I appreciate you doing that.
• They did not come from the executives—not one nickel of PAC money from the pharmaceutical industry.

Transcript Highlights:

• It is the pharmaceutical companies that are the ones setting the high prices of drugs, and we're here
• negotiate with the pharmaceutical negotiate with the pharmaceutical companies<00:31:01.039> to
• <00:33:15.240> companies drugs it's the pharmaceutical companies drugs it's the pharmaceutical
• <00:36:02.119> prices impact pharmaceutical prices impact pharmaceutical prices specifically
• <00:36:21.599> advertising to me is the pharmaceutical advertising to me is the pharmaceutical

Keywords: Meeting Start: 00:00 Roll Call: 00:10 SB145 Discussion: 02:23 SB145 Vote: 05:13 SB183 Discussion: 06:13 SB183 Vote: 11:37 HB413 Discussion Only: 16:15, 958, all

Summary: The House Standing Committee on Banking and Insurance met with a quorum and first took up Senate Bill 145, sponsored by Sen. David Givens. The bill would update retail installment contract statutes for automobile sales, allowing retailers with installment contracts shorter than 28 days to begin collections after three days instead of waiting for multiple missed payments, and it also harmonizes a related dollar amount in statute from $10 to $15. The committee asked no questions, and the bill received a favorable expression on a roll-call vote. The committee then heard Senate Bill 183 from Sen. Matt Nunn, with testimony from Chris Nolan of the American Property Casualty Insurance Association. The bill would require proxy advisers acting for the State Retirement System to act solely in the financial interest of current and future retirees and to avoid political or social considerations in shareholder voting recommendations. Supporters argued it would keep politics out of public pensions and align proxy advice with fiduciary duties; members praised the bill and noted Kentucky could be among the first states to adopt such a model. The committee approved the bill with favorable expression after a roll-call vote. The committee also reviewed administrative regulation 808 KAR 9:10 from the Department of Financial Institutions, with no vote required. It then took up House Bill 413, a PBM rebate pass-through bill, with testimony from Sarah Wood of the Diabetes Patient Advocacy Coalition. She said the bill would require 85% of negotiated drug rebates to be passed through to patients at the point of sale, lowering out-of-pocket costs, especially for high-rebate drugs such as insulin, while still allowing 15% to remain with plans. She cited examples from other states and argued the bill would benefit about 650,000 Kentuckians. Hope McClaflin of Anthem opposed the bill, saying it would reduce employers’ ability to use rebates to lower premiums, could disproportionately favor high-cost brand-name drug users, and could create significant costs for state and fully insured plans. Members asked questions about other states’ pass-through rates and the effect on premiums, but no final action on House Bill 413 was taken in the portion of the meeting provided.

Transcript Highlights:

• And when it comes to pharmaceutical training, we're trained in botanical-pharmaceutical interaction.
• We are trained in botanical-pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• And when it comes to pharmaceutical training, we're trained in botanical, pharmaceutical interaction.
• training were trained in botanical, pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• pharmaceutical pharmaceutical interactions.

Bills: HB946, HB1093, SB26, SB29, SB30, SB195, SB219, SB222, SB255, SB314, SCR2, SCR22

Keywords: healthcare transparency, hospital pricing, consumer protection, collection actions, fines, naturopathic medicine, Louisiana Board of Naturopathic Medicine, licensing, healthcare, prescriptive authority, natural therapies, opioid treatment, regulation, addiction recovery, state law, SB 29, Act 732, coroner, autopsy, child death

Summary: The committee first heard and favorably reported SB 255, which expands the educational qualifications for psychosocial rehabilitation services to include health sciences and therapeutic recreation degrees, and SB 314, which cleans up prior language on community psychiatric support and treatment services so a limited scope certified social worker license can still be issued even if the applicant is slightly late renewing. Members and witnesses said both bills were intended to improve access to behavioral health services, especially in rural areas, and there was no opposition on either measure. The committee then advanced SB 26, which repeals facility need review for opioid treatment programs to make it easier to open more OTPs in Louisiana, and SB 29, which requires child autopsy reports to include immunization records and access to the LINKS vaccine database. SB 29 drew some concern about whether singling out immunizations could imply causation, but the author and supporters said the bill is only about adding data and that the records would be part of broader medical information. Both bills were reported favorably. Members also reported favorably SB 30, as amended, to allow telehealth for obesity/weight-management treatment with synchronous interaction and other safeguards, though some providers warned the language should not unduly limit future board authority. SB 219 was approved to create an Office of Health and Nutrition within LDH, with testimony from the department, the Alzheimer’s Association, and Pennington Biomedical supporting the focus on nutrition, physical activity, and brain health. SB 222 was reported favorably with amendments to reduce duplicative behavioral health administrative requirements, streamline supervision rules, and expand telehealth for psychosocial rehabilitation. The committee also approved SB 195, the “Danny’s Dose” EMS bill, allowing EMS personnel to administer a patient’s own prescribed time-critical medication in emergencies; testimony from families with rare conditions described life-threatening delays under current rules. Finally, SCR 2 was adopted to update hospital construction standards to the most recent Facility Guidelines Institute edition, and SCR 22 was reported favorably to request a more detailed legislative auditor report on opioid settlement spending and outcomes. The committee then began hearing HB 1093 on naturopathic medicine, with the author proposing a licensing framework under the State Board of Medical Examiners and a large amendment set; members raised questions about scope, prescriptive authority, training, and whether the profession should have its own board, but no final action on the bill was taken in the portion provided.

Transcript Highlights:

• This is a voluntary program for pharmaceutical manufacturers.
• Those restrictions come from the pharmaceutical manufacturers themselves. All right.
• The pharmaceuticals are strangling delivery.
• Pharmaceuticals making a heck of a lot of money. But my rural hospitals are not.
• There are over 20,000 pharmaceutical manufacturers.

Transcript Highlights:

• 24:02.160> is Of those trillions, pharmaceutical is Of those trillions, pharmaceutical is the<
• <01:24:13.080> companies pharmaceutical companies pharmaceutical companies spend<01:24:15.600>
• millions of dollars on pharmaceuticals. millions of dollars on pharmaceuticals.
• many pharmaceutical commercials either. many pharmaceutical commercials either.
• profit margin of the pharmaceutical profit margin of the pharmaceutical company?

Keywords: 1187, senate, all

Transcript Highlights:

• And when it comes to pharmaceutical training, we're trained in botanical-pharmaceutical interactions,
• nutraceutical interactions, and pharmaceutical interactions.
• And when it comes to pharmaceutical training, we're trained in botanical, pharmaceutical interaction.
• training were trained in botanical, pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• pharmaceutical pharmaceutical interactions.

Summary: The committee first heard and favorably reported SB 255, which expands eligibility for psychosocial rehabilitation services by adding health sciences and therapeutic recreation degrees to the list of acceptable educational backgrounds. Supporters said the change would help address workforce shortages and improve access in rural areas. SB 314 was then reported favorably; it cleans up prior law so a limited scope certified social worker license can still be used for community psychiatric support and treatment services even if the application is filed after the CSW license has expired, rather than being barred by a timing restriction. The committee next took up several bills by Chairman McMath. SB 26, which repeals facility need review requirements for opioid treatment programs, was reported favorably after members and witnesses said Louisiana has too few OTPs and that removing the review would improve access, especially in rural areas. SB 29, requiring review and reporting of a child’s immunization records in certain unexpected death autopsies, was reported favorably despite questions about whether the bill should refer more broadly to medical records; supporters said the data could help evaluate vaccine-related concerns, while opponents raised concerns about singling out immunizations. SB 30, dealing with telehealth for obesity/weight management, was amended and reported favorably; the committee adopted technical amendments and a conceptual amendment replacing “metabolic condition” with “weight management services,” while witnesses debated patient safety, board authority, and whether the bill should limit agencies’ ability to restrict telehealth in the future. The committee also reported favorably SB 219, which creates an Office of Health and Nutrition within LDH. Supporters from the department, the Alzheimer’s Association, and Pennington Biomedical said the office would strengthen coordination on nutrition, physical activity, and brain health, and cited high Alzheimer’s costs and prevalence in Louisiana. SB 222, which streamlines Medicaid behavioral health administrative requirements and expands telehealth for psychosocial rehabilitation, was reported favorably with amendments after supporters described workforce and rural access barriers. SB 195, the “Danny’s Dose EMS Treatment Act,” was reported favorably; it would allow EMS personnel to administer a patient’s own prescribed time-critical medication in emergencies, and testimony from a parent and physician described life-threatening delays under current practice. The committee also adopted SCR 2, updating hospital architectural standards to the most recent Facility Guidelines Institute edition, and SCR 22, requesting a more detailed legislative auditor report on opioid settlement expenditures; members said they wanted clearer outcome data and planned to refine the language before floor debate. Finally, HB 1093 on naturopathic medicine was introduced and heavily amended, with the bill shifted under LSBME oversight and a large set of changes discussed, but no final action was taken in the portion provided.

Transcript Highlights:

• you discuss why 340B was not included in the help omnibus and what your discussions with the pharmaceutical
• Uh, the discussions weren't with the pharmaceutical companies.
• have had with the pharmaceutical have had with the pharmaceutical industry.<00:19:55.000> Can
• discussions with the pharmaceutical discussions with the pharmaceutical industry<00:20:02.480>
• <00:20:05.960> The pharmaceutical companies. The pharmaceutical companies.

Keywords: 919, house, all

Summary: House Republican leaders in Minnesota gave a post-session recap focused on what they described as major accomplishments in a tied legislature. They highlighted passage of the Office of Inspector General bill to combat fraud, along with tax and fee relief measures including $125 million in property tax relief and $250 million in car tab reductions. They also pointed to funding for hospitals and uncompensated care, county IT modernization, school safety and mental health programs, public official safety at the Capitol and judicial branch, and a $1.2 billion bonding bill for infrastructure. Leaders repeatedly contrasted this session with the prior Democratic trifecta, arguing Republicans blocked new tax increases and helped make government more accountable and affordable. They said the OIG bill had been a top priority, had previously been blocked in the House, and was now signed into law. On health care, they said the final package included support for hospitals and denied that discussions about 340B involved pharmaceutical companies, saying offers on that issue were rejected by House Democrats. In response to questions, leaders said the tie forced public negotiation and that Minnesotans were the real winners because lawmakers worked together. They also defended the lack of final floor votes on gun-related proposals, saying those measures had been voted on multiple times in committee and on the floor but did not have the votes to pass. On transparency, they said the process was as open as possible and that bonding projects had been heard in committee and reviewed by the bonding team before inclusion.

Transcript Highlights:

• Swanson, is that you both talked about pharmaceuticals. I don't think that gets mentioned.
• On the pharmaceutical piece, looking at both nationally and internationally, if we don't move further
• multiplier that the pharmaceutical industry will have to catch up with.
• And I'm assuming you don't have to pump these cells full of pharmaceuticals. No, at all.
• And I'm assuming you don't have to pump these cells full of pharmaceuticals. No, not at all.

Summary: The Select Committee on Alternative Protein Innovation held its first informational hearing to examine the state of alternative protein research, industry growth, and policy needs in California. The chair opened by noting California’s $5 million public investment in UC research in 2022 and framed the hearing around three panels: the climate, environmental, and security potential of alternative proteins; industry scaling and commercialization; and university-led research and workforce development. Members emphasized that the committee will continue with site visits and additional hearings across the state. The first panel focused on the case for alternative proteins as a climate, land, water, biodiversity, and food-security solution. Shana Fertig of the Good Food Institute argued that plant-based, fermentation-derived, and cultivated proteins can reduce greenhouse gas emissions, land use, and water use while helping California meet its climate and conservation goals. Zane Swanson of CSIS added that alternative proteins could reduce risks tied to zoonotic disease, antimicrobial resistance, supply-chain disruption, and broader national security concerns. In questions, members discussed the role of pharmaceuticals in animal agriculture and how alternative proteins might complement, rather than replace, traditional farming by creating new markets for California crops and helping farmers diversify. The second panel featured industry leaders Ethan Brown of Beyond Meat, Myra Passick of Upside Foods, and Arye Elfenbein of Wildtype. Brown highlighted plant-based meat’s health and climate benefits, criticized misinformation campaigns against the sector, and urged better labeling, reduced subsidies for factory farming, and more plant-based food in public institutions. Passick described cultivated meat as a scalable food-production technology, said Upside Foods has already produced millions of pounds annually at its Emeryville facility, and asked for grants, low-interest loans, and possible participation in cap-and-trade or similar revenue programs. Elfenbein described cultivated seafood as a way to address overfishing, contamination, traceability problems, and the heavy import dependence of the U.S. seafood supply, while also noting conservation benefits and the need for California to remain a hub for the industry. The final panel centered on research and workforce development. UCLA’s Amy Rowat described state-funded work on technical bottlenecks such as growing fat cells and creating edible scaffolds, along with a Future Food Fellows program that trains students across science, engineering, law, and policy. UC Santa Cruz economist Galina Hale argued that alternative proteins are necessary to meet future protein demand while reducing food-system emissions, and said California must support the sector through grants, loans, procurement, and research centers to avoid losing leadership to other states and countries. The hearing ended with the chair thanking the witnesses, noting that all materials would be posted online, and saying the committee would continue building policy and budget proposals to support the sector.

Transcript Highlights:

• requires drug pharmaceutical requires drug pharmaceutical manufacturers<00:13:53.080> to<
• And yet today we have pharmaceutical And yet today we have pharmaceutical companies<01:15:04.640
• > the<01:15:30.840> US US pharmaceutical profits in the US US pharmaceutical profits in
• Thanks. or do we stand with the pharmaceutical or do we stand with the pharmaceutical companies<01:18
• pharmaceuticals pharmaceuticals uh<01:30:19.000> and<01:30:19.200> all<01:30:19.320>

Keywords: 1187, senate, all

Transcript Highlights:

• Supply costs have increased on average by 5% since COVID-19 officially ended, and pharmaceutical costs
• We partnered with Amnial Pharmaceuticals through an open request for information process.
• The pharmaceutical sector, as you know, is well known for being secretive and litigious.
• You mentioned the company was Amnial Pharmaceutical. How exactly were they chosen?
• Most pharmaceutical companies have lawsuits against them. That's probably true.

Keywords: 988, house, all

Transcript Highlights:

• I will say Texas has had mandatory pharmaceutical price reporting since 2019.
• And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
• And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
• Thank you, Chairman, Phil Christopher Nellie here with the Pharmaceutical Care Management Association
• This is an idea that came from the pharmaceutical manufacturers.

Summary: The House Insurance Committee met on April 29 with a quorum present and took up several insurance and health care-related bills. SB 192, a dental reimbursement bill, was amended to allow dentists to opt in electronically to credit-card payment methods and to clarify applicability and effective date; it was reported as amended. SB 84 would require prostate cancer screening coverage for men over 40 under current clinical guidelines and prohibit cost-sharing; supporters from the American Cancer Society said Louisiana has a high incidence of prostate cancer and that out-of-pocket costs deter early screening. The committee adopted amendments and reported the bill as amended. SB 275, dealing with reimbursement and network participation for certified registered nurse anesthetists, drew support from nursing and hospital groups and was reported favorably. SB 169, a cleanup bill on biomarker testing, was also amended and reported. The committee spent substantial time on SB 401, which creates a temporary prescription drug affordability board to review pricing data on selected drugs and report findings to the legislature. Supporters said the board would improve transparency and help lawmakers understand drug pricing trends; opponents raised concerns about confidentiality, market effects, and the lack of a defined policy outcome beyond reporting. Amendments narrowed the scope, added confidentiality protections, and removed opposition cards, and the bill was reported as amended. SB 387, a major PBM reform bill tied to SB 401, would change PBM compensation, rebate handling, formulary practices, audits, and appeals, while excluding ERISA plans after discussion and amendment. Supporters argued it would curb spread pricing and other practices that raise costs, while opponents from the Pelican Institute and PCMA warned it would interfere with private contracts, reduce flexibility, and could raise premiums or disrupt city, school board, and small-group plans. After extensive debate and a roll call, SB 387 was reported with amendments by a 10-4 vote. The committee also considered SB 241, which requires certain insurance adjusters and public adjusters to include license numbers in written communications. After amendments limiting the requirement to individual licenses and removing one statutory reference, the bill was reported as amended. Throughout the meeting, members and witnesses repeatedly discussed the need for transparency in drug pricing and PBM practices, the role of ERISA and non-ERISA plans, and potential impacts on public employers and consumers.

Transcript Highlights:

• I will say Texas has had mandatory pharmaceutical price reporting since 2019.
• And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
• And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
• What you're going to hear from the PBMs is they're the only ones that are there keeping pharmaceutical
• This is an idea that came from the pharmaceutical manufacturers.

Keywords: 965, house, all

Summary: The House Insurance Committee met on April 29 with a quorum present and considered several insurance- and health care-related bills. SB 192, concerning dental reimbursement and payment methods, was amended to clarify opt-in for electronic acceptance and then reported as amended. SB 84, which expands prostate cancer screening coverage for men over 40 and bars cost-sharing, was also amended and reported as amended after testimony from the American Cancer Society supporting earlier detection and reduced out-of-pocket barriers. SB 275, dealing with reimbursement and network access for certified registered nurse anesthetists, was reported favorably with broad support from nurse anesthetists, hospitals, and related groups. SB 169, a biomarker testing cleanup bill, was amended to clarify legislative intent and reported as amended. The committee spent substantial time on two major drug-pricing bills. SB 401 would create a Prescription Drug Affordability Board to study selected prescription drug prices, collect manufacturer and related pricing data, and report findings to the legislature; amendments narrowed the scope, addressed confidentiality, and delayed implementation. Supporters said it would provide transparency similar to Texas and help lawmakers understand drug pricing, while opponents warned about government overreach and confidentiality concerns. SB 387, the companion PBM reform bill, would restrict PBM compensation to flat fees and performance bonuses, require rebate pass-throughs, limit formulary practices, expand audit and reporting requirements, and create enforcement mechanisms; it was amended to delay implementation, refine definitions, and address ERISA-related concerns. Supporters argued it would curb PBM abuses and lower drug costs, while opponents from the Pelican Institute and PCMA said it would interfere with private contracts, reduce flexibility, and could raise premiums. After a roll call vote, SB 387 was reported with amendments. The committee also took up SB 241, which requires certain insurance adjusters and appraisers to include license numbers in written communications. After amendments narrowing the requirement to individual claims and public adjusters, the bill was reported as amended. Throughout the meeting, members repeatedly raised concerns about unintended consequences, especially for cities, school boards, and other non-ERISA plans, and sponsors said they would continue working on the drug-pricing bills before floor consideration.

Transcript Highlights:

• How senators are stepping up enforcement efforts in the pharmaceutical industry to lower healthcare costs
• It's a federal program, and it's a good one that said pharmaceutical companies need to provide our safety
• It is raising costs of pharmaceuticals, and it's not helping patients.
• <00:11:46.640> and raising costs of pharmaceuticals and raising costs of pharmaceuticals and it's
• medical companies pharmaceutical medical companies pharmaceutical companies<00:12:09.520> are

Keywords: 1187, senate, all

Transcript Highlights:

• requiring prescription drug manufacturers to notify the Attorney General of arrangements between pharmaceutical
• By no means a patent attorney, particularly in the field of pharmaceuticals, but my understanding from
• duplicate process that the state is already governed by the federal government and we're dealing with pharmaceutical
• It's been raised by the pharmaceutical industry that this may actually...
• It's been raised by the pharmaceutical industry that this may actually... Thank you.

Keywords: 993, senate, all

Summary: The Senate Finance Committee, chaired for the day by Senator John Liu, took up a long agenda of bills covering labor and benefits, corrections, health, taxation, government transparency, and public services. Early measures included increasing short-term disability benefits, adjusting a poverty-level-related earned income disregard, expanding correctional health staffing review, and authorizing the Inspector General to investigate sexual assault complaints in correctional facilities; each of these advanced to the floor. The committee also advanced bills on ovarian cancer screening access, retirement system membership changes, a trail stewardship program, live agency representative access, FOIL/open meetings fee awards, a Harriman campus development plan, court data reporting, educator conventions, park water testing, an energy storage tax abatement, a Native American Affairs office, adult changing tables in public facilities, Medicaid Inspector General audit standards, remote training certification for agency personnel, newborn Gaucher disease testing, electronic self-exclusion requests for gambling, and child daycare inspections and opioid antagonist requirements. Several bills drew discussion. The prescription drug transparency bill (Print 488A) prompted questions about possible overlap with federal Hatch-Waxman/FTC oversight and whether a New York notice requirement could slow generic-drug settlements; sponsors and staff said it was intended as a supplemental transparency measure for consumers. The court reporting bill (Print 1849A) raised concerns about mandates on local governments, but supporters said it mainly required OCA to compile data in one format. The Medicaid local-share phaseout bill (Print 5519) generated the most debate, with supporters arguing it would provide major property tax relief and should be addressed in the budget, while opponents emphasized the need to curb Medicaid fraud, waste, and abuse first. Two major fiscal oversight proposals were defeated. Print 8661, which would have required the Comptroller to hire an independent private auditing firm to review state-funded programs for fraud and abuse, was opposed despite support from some members who argued outside auditing was overdue; it failed by one vote. Print 5519 was also ultimately defeated after a recount confirmed it lacked the required majority of the full 22-member committee. Most other bills were approved and sent either to the floor or, in the case of the drug transparency bill, to the Rules Committee.

Transcript Highlights:

• It didn't come from pharmaceutical companies. They are not involved with this.
• It didn't come from pharmaceutical It didn't come from pharmaceutical companies.<00:35:44.040>
• , in licensing and sale of pharmaceuticals.
• , in the development of pharmaceuticals, in the development of pharmaceuticals, in<00:45:21.000><
• And we also have these pharmaceuticals.

Keywords: 981, all

Summary: The Senate met with a quorum, approved the journal, and then proceeded out of order to consider Senate Joint Resolution 20, recognizing April 9, 2026, as Home Education Day in Colorado. Senator Pelton spoke in strong support of home education, describing it as a parent-led choice that benefits students and families. The resolution was adopted on a 30-0 vote, and the current roll was added as co-sponsors. The chamber then took up the consent calendar and passed House Bill 1229, House Bill 1244, and Senate Bill 153. HB 1229, which concerns the human-animal bond as a social determinant of health, drew three no votes from Senators Pelton, Zamora Wilson, and Baeza; the other two measures passed unanimously. The Senate also laid over third reading of bills until Friday, April 10. In Committee of the Whole, senators considered Senate Bill 72, which increases criminal penalties for assaultive conduct involving a motor vehicle and adds causing death with a motor vehicle to criminally negligent homicide. The committee adopted the report and advanced the bill on second reading. Later, the chamber laid over Senate Bill 134 and House Bill 1084 until April 10, and then took up Senate Bill 140, which would exempt certain rare disease and plasma therapies from review by the Prescription Drug Affordability Review Board. Sponsors and supporters argued the bill protects access for patients with rare diseases and prevents harm to treatment development, while opponents said it would weaken the PDAB’s affordability work and was too broad. Senators Weisman and Gonzales spoke against the bill, with Weisman citing concerns about the federal definition used and Gonzales defending the PDAB’s role in lowering drug costs; the debate continued in the transcript without a final vote shown.